Novavax Inc (NVAX)
$16.39
1.45 (9.71%)
NVAX Stock Quote Delayed 30 Minutes
4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains
Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.22B
PE Ratio
-5.12
EPS
-3.2
Volume (Avg. Vol.)
6.80M
Day's Range
$14.65 - $16.45
52-Week Range
$3.53 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Overlook Novavax at the Risk of Incurring an Opportunity Cost
Although Pfizer and Moderna have stolen the headlines, there are still ample opportunities for upside with NVAX stock.
Vaccines Aren’t Winner-Take-All, Making Novavax Stock a Smart Covid Play
Owners of NVAX stock should not be discouraged by the recent positive results by vaccine makers Pfizer and Moderna.
The Red Ink on Novavax Only Hides Its True Potential
As rival coronavirus vaccines generate exciting headlines, NVAX stock has fallen out of favor with Wall Street. However, this is a mistake as Novavax’s vaccine candidate offers a superior holistic solution.
Sell Novavax Stock After Its Huge Gain
NVAX stock has a nearly $6 billion market cap based on a COVID-19 vaccine that may not work. The firm has a history of cashing in on hype.
With Pfizer Winning the Vaccine Race, Novavax Is a Strong Sell
Novavax made a valiant effort at developing the leading Covid-19 vaccine, but it fell short. Now poor earnings will sink NVAX stock.
Novavax Steals Some of Pfizer’s Thunder With Fast Track Designation
Novavax delivered good news Nov. 9. It announced its Covid-19 vaccine’s been fast-tracked by the FDA. That’s very good news for NVAX stock.
Don’t Expect Massive Short-Term Gains in Novavax Stock Right Now
NVAX stock has promise after Phase 3 data is released, but investors will have to be ready and willing to play the long game.
Stick with Novavax as the Vaccine Competition Goes Global
Many traders have been counting on NVAX stock to be the winner of the Covid-19 vaccine race. Their argument just got a lot stronger.
Novavax May Profit From Life in the Slow Lane
Novavax is attempting to bring a Covid-19 vaccine to market in a new way. This makes NVAX stock a risk with potential rewards.
Without Positive Vaccine News, Novavax May Fall Further
NVAX stock is likely to stay under further pressure until it can release more positive clinical data
How Novavax Has a 2-Pronged Approach to Vaccine Sales
NVAX stock is faring worse than its peers as investors await more positive clinical data from the company.
Novavax Stock Might Actually Win This War of Attrition
Though Novavax stock is looking like the antithesis of its former self in the first half of this year, the wildness detracts from what could be the breakthrough name in the novel coronavirus vaccine race.
Vaccine Hopeful Novavax Could Be Worth a Shot
It's too soon to name Novavax the leader in developing a novel coronavirus vaccine. But NVAX stock is worth watching through the end of 2020.
Fear of Missing Out Could Send Novavax as High as $200
Even after running 1,163% higher, NVAX stock is still a relevant novel coronavirus buy on the recent pullback -- with FOMO and immediate need driving its price.
Can Novavax Stock Overcome Growing Vaccine Distrust?
NVAX stock may be riding high on AstraZeneca's clinical trial blunder, but the path forward is not smooth for Novavax. Here's why.
Coronavirus Hype Is Pushing Novavax to Unrealistic Highs
NVAX stock has to produce the goods before the markets reward it again, as brownie points for gathering funds will only take them so far.
Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?
NVAX stock may actually rise meaningfully above its current levels, as its coronavirus vaccine could still be very profitable.
